文献速递妇科

妇科恶性肿瘤中MAPK-ERK通路基因组改变谱:新型治疗策略的机遇

The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
PubMed 文献 · Gynecol Oncol · 2023-08-30

该研究利用美国癌症研究协会基因组学证据肿瘤信息交换公开数据集(v13.0),纳入10,233例卵巢、子宫和宫颈恶性肿瘤患者,分析MAPK/ERK通路基因改变的发生率。结果显示总体发生率为21%,最常见为KRAS(13%),在卵巢黏液性癌(71%)、低级别浆液性卵巢癌(48%)、卵巢子宫内膜样癌(37%)和子宫内膜样子宫内膜癌(34%)中发生率最高。作者认为约五分之一的妇科肿瘤患者存在MAPK/ERK通路基因组改变,有必要开发针对这些改变的新型治疗策略。

要点

  • 妇科恶性肿瘤中MAPK/ERK通路基因改变的总体发生率为21%,KRAS最常见(13%)。
  • 卵巢黏液性癌(71%)、低级别浆液性卵巢癌(48%)、卵巢子宫内膜样癌(37%)和子宫内膜样子宫内膜癌(34%)中MAPK/ERK通路改变发生率最高。
  • 作者认为针对这些改变的新型治疗策略有待开发。

核心结论

  • 约五分之一的妇科肿瘤患者存在MAPK/ERK通路基因组改变,有必要开发针对这些改变的新型治疗策略。

研究设计与样本

  • 研究利用美国癌症研究协会基因组学证据肿瘤信息交换公开数据集(v13.0),纳入卵巢、子宫和宫颈恶性肿瘤患者共10,233例,按肿瘤部位和组织学分层分析MAPK/ERK通路基因改变(体细胞突变和/或结构染色体改变)的患病率。
  • 纳入分析的RAS-MAPK通路基因包括KRAS、NRAS、BRAF、HRAS、MAP2K1、RAF1、PTPN11、NF1和ARAF,致病性基因改变依据cBioPortal提供的OncoKB数据库数据判定。

主要发现

  • 共纳入10,233例妇科恶性肿瘤患者,其中卵巢癌占48.2%(n=4937),子宫癌占45.2%(n=4621),宫颈癌占6.6%(n=675)。
  • MAPK通路基因改变的总体发生率为21%;最常见改变基因为KRAS(13%),其次为NF1(7%)、NRAS(1.3%)和BRAF(1.2%)。
  • MAPK通路基因改变发生率最高的亚型为卵巢黏液性癌(71%)、低级别浆液性卵巢癌(48%)、卵巢子宫内膜样癌(37%)和子宫内膜样子宫内膜癌(34%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the incidence of MAPK/ERK pathway genomic alterations among patients with gynecologic malignancies. METHODS: We accessed the American Association of Cancer Research Genomics Evidence of Neoplasia Information Exchange publicly available dataset (v13.0). Patients with malignant tumors of the ovary, uterus, and cervix were identified. Following stratification by tumor site and histology, we examined the prevalence of MAPK/ERK pathway gene alterations (somatic mutation, and/or structural chromosome alterations). We included the following RAS-MAPK pathway genes known to be implicated in the dysregulation of the pathway; KRAS, NRAS, BRAF, HRAS, MAP2K1, RAF1, PTPN11, NF1, and ARAF. Data from the OncoKB database, as provided by cBioPortal, were utilized to determine pathogenic gene alterations. RESULTS: We identified a total of 10,233 patients with gynecologic malignancies; 48.2% (n = 4937) with ovarian, 45.2% (n = 4621) with uterine and 6.6% (n = 675) with cervical cancer respectively. The overall incidence of MAPK pathway gene alterations was 21%; the most commonly altered gene was KRAS (13%), followed by NF1 (7%), NRAS (1.3%), and BRAF (1.2%). The highest incidence was observed among patients with mucinous ovarian (71%), low-grade serous ovarian (48%), endometrioid ovarian (37%), and endometrioid endometrial carcinoma (34%). CONCLUSIONS: Approximately 1 in 5 patients with a gynecologic tumor harbor a MAPK/ERK pathway genomic alteration. Novel treatment strategies capitalizing on these alterations are warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nasioudis D, Fernandez ML, Wong N, et al. The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches. Gynecol Oncol. 2023. PMID: 37657193. doi:10.1016/j.ygyno.2023.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。